GlobeNewswire

StackPath and Server Density Merge

Dela

Brings Industry-Leading Monitoring to StackPath's Secure Edge Services Platform

 

DALLAS, May 14, 2018 (GLOBE NEWSWIRE) -- Server Density, a provider of proactive infrastructure monitoring for cloud, servers, and websites, is merging with StackPath, a leading secure edge services platform provider. Server Density enables users to monitor their websites and servers in the cloud or on-prem from a single console and API to easily diagnose problems, maintain uptime and maximize server performance. The service will be integrated and offered as part of the StackPath platform in the very near future.

"We're thrilled to have Server Density become part of our company. It's a perfect fit," said Lance Crosby, founder, chairman and CEO of StackPath. "StackPath has the highest commitment to providing our customers frictionless services, complete visibility into their solutions, and building strong relationships with the open source community and the industry at large. Server Density has followed the same commitments as it built exceptional technologies that are second to none and grew operations at cloud scale."

The Server Density monitoring agent is installed on millions of servers, collecting more than 12-billion metrics each day. The service has more than 100 official integrations with other solutions and platforms, processes more than 300TB of data per month and has availability probes in more than 28 different geographies. Its 1,000+ customers across 75 different countries span all sizes and industries, such as and including the UK's National Health Service (NHS), eCommerce company Firebox, and online game platform Stormancer.

"We created Server Density out of the frustration that monitoring tools were either too expensive, too complex, or both," David Mytton, Server Density co-founder and CEO said. "It's gratifying to see how well our tools have been received, not only by customers, but by developers and companies that have built on the code that we've open sourced. My team and I are excited to bring Server Density into the StackPath platform and accelerate even more evolutionary ways to leverage these technologies."

In addition to its monitoring service, in 2016 Server Density created HumanOps a community that gets people talking about the human aspects of running infrastructure. Companies such as Spotify, PagerDuty, Yelp and Facebook have contributed to sharing ideas and best practices for life on call, dealing with technical debt, fatigue and stress at events around the world, including the UK, US, France, Germany, Poland and more.

"HumanOps is a brilliant and long overdue resource for cloud workers and companies. This industry is evolving faster than any before it, requiring operations of unprecedented scale and solutions at unbelievable speed," said Mr. Crosby. "It takes its toll on people-humans don't have a 100% uptime SLA. We're looking forward to doing even more with HumanOps as part of StackPath."

In December 2015, Server Density raised $1.5 million in seed funding led by SP Ventures. They previously had raised €50k from Seedcamp and funding from angel investors Christoph Janz, Dick Williams, Qamar Aziz, and others. Financial details of the transaction are not being disclosed. Moving forward, the Server Density team in London will serve as the core of StackPath monitoring service team and London will become StackPath's European headquarters.

About StackPath
StackPath is a platform of secure internet services including CDNWAF and DDoS mitigation built at the cloud's edge. StackPath services enable developers at organizations of any size to build protection and performance into any cloud-based solution-from SaaS to web publishing, gaming, media streaming and beyond-without needing cloud security and delivery expertise of their own. More than one million customers, ranging from early-stage companies to Fortune 100 organizations, use StackPath services. Headquartered in Dallas, Texas, StackPath has offices across the U.S. and around the world. For more information, visit stackpath.com and follow StackPath at www.fb.com/stackpathllc and www.twitter.com/stackpath.

About Server Density
Server Density offers SaaS-based scalable infrastructure monitoring to help businesses save time and money. With advanced server and website monitoring alerts, graphing tools and integrations with all major cloud service providers, Server Density's robust and scalable solution helps businesses and IT operations teams be more responsive to issues, make their websites faster and minimize downtime. Founded by David Mytton in 2009 and based in London, Server Density monitors mission critical IT infrastructure for more than 1,000 customers.

For more information, media and analysts may contact
Susie McDonald
StackPath
VP Corporate Communications
susan.mcdonald@stackpath.com 
503-806-3841




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: StackPath via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum